PDF Summary:American Cartel, by Scott Higham and Sari Horwitz

The opioid crisis has devastated communities across the United States, claiming hundreds of thousands of lives. In American Cartel, Scott Higham and Sari Horwitz investigate the systemic failures that enabled this epidemic. They reveal how pharmaceutical companies fueled the crisis through aggressive marketing tactics that downplayed the risks of addiction. The authors also expose the companies' efforts to undermine the Drug Enforcement Administration's attempts at regulation.

Higham and Horwitz document how drug distributors flooded towns with painkillers, ignoring suspicious orders. They explore the complex reasons behind the DEA's declining enforcement power, from a new law that weakened their authority to the "revolving door" between the agency and private industry. While lawsuits aimed to hold companies accountable, the human cost of the opioid disaster continued to mount—straining social services, law enforcement, and family ties.

(continued)...

Context

• Jamie Gorelick is a well-known attorney with extensive experience in government, having served in high-level positions, which gave her significant clout and the ability to negotiate with top officials.

Other Perspectives

• The industry's engagement with influential individuals could be a legitimate part of the legal and regulatory process, where companies have the right to representation and to make their case to regulators.
• The hiring of former officials could be part of a company's due diligence to ensure that their practices are in line with current legal interpretations and to avoid unintentional regulatory breaches.
• The involvement of high-profile attorneys in negotiations with the government is a common legal practice and does not necessarily indicate improper conduct or undue influence on the part of the Justice Department officials.
• The use of the term "interfere" presupposes a negative intent; attorneys advocating for their clients' interests is a fundamental aspect of the legal system and not necessarily an interference.

The industry's effective campaign to weaken federal regulations and laws related to opioid distribution.

The authors highlight how the pharmaceutical sector effectively hindered actions meant to regulate by the DEA, including the passage of the Marino-Blackburn bill and the promotion of limitations on the DEA's ability to utilize the ARCOS database.

The law supported by Marino and Blackburn considerably heightened the challenges faced by the DEA in swiftly suspending the activities of firms, even when they blatantly violated legal rules.

The passage of the legislation sponsored by Marino and Blackburn marked a critical juncture that greatly reduced the Drug Enforcement Administration's ability to oversee the secure distribution network of pharmaceuticals. In 2016, after significant influence and monetary contributions to political campaigns from the pharmaceutical sector, the bill was unanimously passed in both houses of Congress. The departure of key adversaries, including the DEA's past chief Michele Leonhart and former Attorney General Eric Holder, facilitated the progress of the legislation.

The main components of the legislation achieved the industry's goals by changing the standards for issuing Immediate Suspension Orders, consequently diminishing the Drug Enforcement Administration's ability to uphold regulations. The DEA now faced the increased challenge of proving that a company's conduct was likely to result in death or grave harm, which made arguing such cases in federal court considerably more difficult. Companies remained able to circumvent legal restrictions by implementing measures for rectification. The DEA's principal administrative law judge, John J. Mulrooney, criticized in a scholarly legal article how the recent law significantly weakened the DEA's ability to swiftly suspend the operations of a drug company.

Practical Tips

• You can become more informed about legislative changes by subscribing to a service that tracks and explains new laws in layman's terms. This will help you understand the impact of such laws on various sectors, including your own, and how they might affect your rights or business practices. For example, if a new law affects pharmaceutical regulations, you'll be better prepared to discuss and address these changes proactively.
• Engage in shareholder activism if you own stocks in pharmaceutical companies by attending shareholder meetings and asking questions about their political contributions and lobbying efforts. This can help hold companies accountable for their influence on legislation and encourage more transparent practices.
• Engage with your local community by attending town hall meetings to understand firsthand how support from key figures can influence public opinion. Listen to the arguments presented and observe how endorsements from respected community members or local leaders sway the discussion. This will provide a practical understanding of the dynamics of influence and support in a legislative context.
• Engage with a peer group from your industry to share insights and strategies for staying ahead of legal requirements. This could be an informal monthly meetup or an online forum where you exchange ideas on compliance and corrective measures. If you're in the tech industry, you might discuss how to implement user consent mechanisms to comply with digital privacy laws.
• Start a discussion group focused on consumer protection and corporate responsibility. By gathering friends or community members to talk about recent news involving corporate misconduct, you can explore the complexities of proving harm and brainstorm what evidence you would need to show it.

The industry's conduct hindered the Drug Enforcement Administration's capacity to oversee the ARCOS system that monitors opioid distribution, thus obstructing the agency's efforts to identify suspicious activities.

This sub-section explores how the influence exerted by pharmaceutical companies' lobbying efforts resulted in the passage of legislation like the Marino-Blackburn bill, while concurrently weakening the Drug Enforcement Administration's capacity to access essential information and oversight related to the opioid distribution network. The authors detail the meticulous tracking of every painkiller's path in the United States, from its manufacture through the volumes dispatched by distributors to pharmacies, to the precise locations where these medications are stocked and provided to patients. For an extended period, those involved in the drug industry, particularly distributors, expressed frustration over their inability to access the database, arguing that this limitation impeded their full understanding of the drug distribution process and consequently their capacity to identify and address potentially suspicious orders.

However, the authors expose the grievance as lacking genuineness. Pharmaceutical companies meticulously monitor the amounts of pills distributed to different pharmacies, data that forms the basis of the ARCOS database. Internal emails disclose that the industry's trade organization, the HDA, was secretly devising strategies to sway legislative actions in a manner that would limit the Drug Enforcement Administration's capacity to access specific data, thus hindering the agency's capability to scrutinize the same data that pharmaceutical firms use to oversee their operations.

Practical Tips

• You can enhance your personal data privacy by regularly auditing and updating your privacy settings on social media and other online platforms. By doing this, you take control of who has access to your information, much like an organization controlling data access. For example, dive into the privacy settings of each platform you use and restrict access to your posts, friends list, and personal information to friends only or even more selectively.

Other Perspectives

• There could be an argument that the ARCOS system itself had inherent limitations or inefficiencies that hindered the DEA's oversight capabilities, which were not directly related to the industry's conduct.
• The legislation in question could have been supported by a broader coalition with diverse interests, not solely by pharmaceutical companies, suggesting that the weakening of the DEA's access was not the primary goal.
• The ARCOS system, while designed to track painkillers, may not capture all transactions if entities fail to report accurately or if there are gaps in the data collection process.
• Limited access to the ARCOS database for distributors could be a necessary measure to maintain the integrity and security of sensitive drug distribution data.
• Pharmaceutical companies may monitor pill distribution data, but this does not necessarily mean they have the expertise or the regulatory mandate to analyze this data for signs of diversion or abuse as the DEA does.
• The DEA may have had the ability to adapt to the changes imposed by the industry's actions and find alternative ways to monitor suspicious activities effectively.

The initiation of lawsuits targeted at pharmaceutical firms and the strategies used in the extensive opioid litigation.

In this section of "American Cartel," the narrative unfolds to show how various cities and Native American tribes initiated lawsuits against pharmaceutical companies, holding them accountable for their role in the opioid crisis, after a time when the enforcement capabilities of the DEA were reduced. The authors describe how the plaintiff's legal team employed novel legal strategies, such as claims of public nuisance, and established a broad coalition of legal practices to challenge some of the nation's most powerful companies.

Lawyers like Paul Farrell, who acted on behalf of the plaintiffs, employed novel legal strategies like public nuisance claims to hold the industry accountable via the courts.

In this segment, the story focuses on Paul Farrell, a lawyer from Huntington, West Virginia, who employs novel tactics to hold pharmaceutical companies accountable. The book details how Farrell utilized public nuisance law, comparing the flood of pain pills into communities by corporations to the dangerous dumping of toxic substances, as a strategy to tackle the widespread opioid epidemic.

Farrell and his attorneys spurred numerous communities into taking a host of legal measures against the manufacturers, distributors, and dispensers of opioids as a reaction to the opioid crisis.

Upon uncovering the staggering fact that drug distributors had saturated West Virginia with 780 million doses of oxycodone and hydrocodone, Farrell initiated a series of public nuisance lawsuits on behalf of the towns, cities, and counties devastated by the opioid crisis. The book details how Farrell, in collaboration with a team of esteemed legal representatives for the plaintiffs, galvanized the communities most impacted to convince local officials to join the lawsuit. Community leaders, alarmed by the escalating number of overdose fatalities, adopted a legal approach pioneered by Farrell in their pursuit of accountability and financial aid to address the crisis.

Context

• These lawsuits often face significant legal challenges, including proving causation and the extent of the companies' responsibility for the crisis.
• These are prescription opioids used to treat moderate to severe pain. They are highly addictive and have been central to the opioid epidemic due to over-prescription and illegal distribution.
• Public nuisance lawsuits are legal actions that claim a party's actions have interfered with the public's rights or interests, often used in environmental or public health contexts.
• The involvement of community leaders in legal actions reflects a broader trend of local governments seeking justice and resources to address public health challenges exacerbated by corporate practices.
• Successful lawsuits can result in financial settlements that provide funds to affected communities. These funds are often used for addiction treatment programs, public health initiatives, and other community support services to mitigate the impact of the crisis.

The attorney formed a coalition of prominent law firms specializing in plaintiffs' cases to pool resources and coordinate a complex, multi-pronged legal strategy.

Farrell adopted a collaborative strategy with leading mass tort lawyers to tackle the daunting task of taking on powerful entities like McKesson, Cardinal Health, and AmerisourceBergen. The book chronicles Farrell's work in uniting a powerful coalition of affluent legal practices and numerous experienced lawyers adept in handling lawsuits concerning defective drugs, medical devices, environmental hazards, and tobacco. Farrell worked closely with his team to amass compelling evidence, interrogate key witnesses, formulate strategies for the trial, and resolutely confront the highly paid defense attorneys representing the pharmaceutical industry.

The authors argue that what started as a grassroots effort in West Virginia grew into a substantial nationwide initiative that effectively instigated comprehensive changes and corporate responsibility for their role in the opioid epidemic.

Context

• Similar coalitions have been formed in the past for major litigation efforts, such as those against tobacco companies or asbestos manufacturers, which have led to significant legal and financial outcomes.
• The concept of corporate responsibility in this context involves holding companies accountable for their role in public health crises, ensuring they take steps to prevent future harm and compensate affected communities.
• The legal strategy in such cases often involves gathering extensive evidence, including internal documents from companies, expert testimonies, and data analysis to demonstrate negligence or misconduct.
• The grassroots nature of the initiative suggests it began with local communities and individuals affected by the opioid crisis, eventually gaining momentum and support on a national scale.
• Handling cases involving defective drugs and medical devices requires a deep understanding of scientific and technical details. Lawyers often collaborate with experts in fields like pharmacology, toxicology, and engineering to build robust cases.
• Defense attorneys in such cases are typically hired by large corporations to protect their interests, often employing extensive resources and legal expertise to challenge claims and minimize liability.
• Local attorneys in West Virginia played a crucial role in initiating lawsuits, gathering evidence, and building cases that would later be expanded upon by larger coalitions of law firms.
• This legal approach involves numerous plaintiffs against one or a few defendants in state or federal court, often used in cases involving widespread harm from products or actions, such as the opioid crisis.
• The legal pressure and public scrutiny forced companies to acknowledge their role in the crisis and implement measures to prevent future abuses, such as improving compliance programs and increasing transparency in their operations.

Judge Dan Aaron Polster supervised the merging of various lawsuits into a unified legal proceeding known as Multi-District Litigation.

Communities across the country flooded the United States judicial system with a vast array of lawsuits targeting the opioid sector. In 2017, the authors detail how multiple legal cases were consolidated into a single court action, referred to as MDL, under the supervision of a specific jurist, who was responsible for managing the complex legal activities.

The plaintiffs' legal counsel was cautious about rushing to a settlement, convinced of their strong case and ready to proceed to trial despite the judge's recommendation for a swift resolution.

During the first MDL meeting in January 2018, Judge Polster caught the attending lawyers off guard by pushing for a rapid settlement that would serve the public interest instead of a protracted courtroom fight. He was acutely aware of the critical nature of the opioid crisis and the alarming rate of fatalities due to excessive consumption of these drugs. He also harbored concerns regarding the legal system's preparedness to tackle a public health crisis as it emerged. The legal representatives of the plaintiffs remained steadfast in their decision to reject a quick settlement, persuaded that the damning evidence they had unearthed before the trial justified a legal confrontation to aim for significant financial recompense for their clients.

Context

• The epidemic has resulted in substantial economic costs, including healthcare expenses, lost productivity, and increased law enforcement and legal costs.
• The opioid crisis refers to the widespread misuse of both prescription and non-prescription opioid drugs in the United States, leading to significant increases in addiction, overdoses, and deaths.

Other Perspectives

• By settling, the plaintiffs might avoid the emotional toll and public exposure that often accompany a high-profile trial.
• The legal counsel's strategy might not consider the risk of setting a precedent that could negatively impact future litigation related to similar public health crises.
• The counsel's stance could be interpreted as potentially prioritizing a larger financial compensation over a quicker resolution that might better serve the immediate needs of those affected by the crisis.
• The judge's recommendation for a quick settlement could be seen as undermining the plaintiffs' right to a fair trial, where all evidence and arguments can be presented and scrutinized in detail.
• The public interest is not always best served by rapid resolutions; in some cases, a thorough and public trial process might be more beneficial for society in the long term, as it can lead to systemic changes and reforms.
• The adversarial nature of the legal system can bring to light important information and lead to more comprehensive solutions than a quick settlement might.
• Rejecting a quick settlement may prolong the legal process, potentially delaying compensation for those affected by the opioid crisis.
• The evidence, while damning, may not be sufficient to cover the scope of the allegations, and additional evidence might be required to strengthen the case.
• The pursuit of financial recompense might overshadow the need for systemic changes in industry practices or regulations that could prevent future harm.

The MDL was characterized by fierce disagreements as corporations aimed to hide harmful data, especially concerning the availability of the registry monitoring the distribution of regulated substances.

This sub-section outlines the intense legal battles that unfolded in the discovery stage of the MDL, with defense attorneys opposing the plaintiffs' demands to examine corporate correspondences, internal assessments, marketing tactics, as well as the methods used by the DEA to oversee the records of controlled substances distribution. The companies utilized strategies that involved asserting the detrimental information was shielded by attorney-client confidentiality. The authors highlight instances where the department responsible for law enforcement often sided with the arguments presented by the defense, contending that revealing details like the ARCOS data might impede active criminal investigations and pose risks to public safety. In 2019, The Washington Post commenced litigation which resulted in making the ARCOS data public by utilizing the Freedom of Information Act to obtain the data.

Context

• MDL stands for Multidistrict Litigation, a legal procedure designed to consolidate complex cases from different districts to streamline pretrial processes, often used in large-scale corporate litigation.
• Defense arguments often cite public safety to justify withholding information, suggesting that disclosure could compromise law enforcement efforts or lead to misuse of sensitive data.
• This U.S. law allows for the full or partial disclosure of previously unreleased information and documents controlled by the government, promoting transparency and accountability.
• The privilege typically covers legal advice and strategy discussions but does not protect communications made for the purpose of committing a crime or fraud.
• The release of ARCOS data, as pursued by The Washington Post, highlighted the scale of opioid distribution and contributed to public understanding of the opioid crisis, influencing policy and legal actions.
• As a major American newspaper, The Washington Post has a history of investigative journalism, often using FOIA requests to uncover information of public interest, particularly in cases involving government oversight and corporate accountability.

The thorough legal strategy targeted all tiers involved in the opioid distribution chain.

This section of the book scrutinizes the strategy employed by the plaintiffs, recognizing the difficulties in securing criminal convictions against the corporations or their executives, and devises an all-encompassing plan to make the whole network responsible for opioid distribution answerable through lawsuits in civil court. The main goal was to secure financial support to assist regions devastated by the opioid epidemic and to overhaul the processes of production, distribution, and the issuance of opioids to prevent additional harm.

Manufacturers were accused of employing promotional tactics that downplayed the risk of becoming dependent on opioid medications.

The book outlines the lawsuits directed at drug manufacturers, emphasizing the actions of a specific company that downplayed the potential for opioid dependency while aggressively marketing their pain relievers as safe from addiction and appropriate for a range of ailments. This involved working closely with organizations that advocated for the welfare of pain patients, which appeared to be autonomous groups fighting for patient rights but often obtained hidden funding from drug companies and generously paid doctors for lectures that promoted the broader application of opioids for pain management.

The companies' promotional tactics markedly altered the discourse surrounding pain management in the United States, which led to an increase in the quantity of opioid prescriptions issued by medical professionals, in tandem with the Drug Enforcement Administration's approval of elevated production quotas for certain analgesics, an action that the firms justified by pointing to a legitimate need for these drugs.

Context

• Companies often recruited influential doctors, known as key opinion leaders, to endorse their products. These doctors would give talks, publish articles, and influence their peers, lending credibility to the companies' claims.
• At the time, there was insufficient regulatory oversight on the marketing practices of pharmaceutical companies, allowing misleading information to proliferate.
• These organizations, often referred to as "front groups," are set up to appear independent but are actually funded by companies to promote specific agendas that benefit the funders.
• Sponsored lectures can become a primary source of information for some doctors, especially in areas with limited access to independent medical education, potentially skewing their understanding of treatment options.
• The change in discourse led to policy shifts that prioritized pain treatment, sometimes at the expense of considering the risks of addiction and dependency.
• Production quotas are limits set by the DEA on the amount of a controlled substance that can be legally manufactured in the U.S. each year, intended to balance medical needs with the potential for abuse.

Distributors came under examination for flooding communities with excessive opioid shipments and failing to notify authorities about transactions that were potentially suspicious.

Higham and Horwitz describe the core of the legal actions against pharmaceutical distributors as allegations that these companies flooded communities with an overabundance of opioid prescriptions and failed to alert the DEA about obvious signs of the medications being diverted to illegitimate channels. The book details how corporations like McKesson, Cardinal Health, and AmerisourceBergen created a distribution system that emphasized profit-making, even in the face of warnings from the Drug Enforcement Administration and its official, Joseph Rannazzisi, while failing to adequately oversee atypical orders.

The authors highlight that, even though there were worries about pharmacies channeling medications into the black market, the distributors often raised the thresholds for these pharmacies without performing thorough background checks. In presenting their argument, the authors assert that these corporations failed to fulfill their legal duty to protect the public by properly overseeing the supply chains of prescription painkillers.

Other Perspectives

• It could be argued that the term "flooding" is subjective and that distributors were providing a supply to meet what they perceived as legitimate demand.
• The emphasis on profit-making is a characteristic of most businesses, and without evidence of intentional wrongdoing, it could be argued that distributors were simply engaging in standard business practices.
• Profit maximization could be seen as a response to competitive pressures within the industry, rather than a disregard for public health.
• Distributors may argue that the DEA's warnings were not sufficiently clear or actionable, leading to confusion about the appropriate steps to take.
• There may have been a lack of clarity or legal standards defining what constitutes a "thorough" background check, which could have led to inconsistencies in how distributors assessed pharmacy orders.
• It could be suggested that the corporations were operating in a highly competitive market and that the regulatory environment allowed for the practices that later came under scrutiny.
• It could be argued that the responsibility for overseeing the supply chains should not rest solely on distributors, but also on other stakeholders, including manufacturers, prescribers, and regulatory bodies.

Pharmacy chains are being held responsible for the distribution of substantial quantities of painkillers without proper oversight.

The book examines the intense examination pharmacy chains underwent for their participation in the opioid crisis, despite their claims that they were merely dispensing valid prescriptions written by licensed doctors. Chains like CVS, Walgreens, and Rite Aid dispensed staggering quantities of painkillers, often without asking questions about obvious red flags, such as long lines of customers at odd hours, vehicles bearing license plates from other states waiting in pharmacy drive-through lanes, and numerous individuals who opted to pay for their prescriptions with cash, indicating the possibility that the medication could end up in unauthorized transactions.

Certain pharmacy chains provided financial rewards to their pharmacists as an encouragement to dispense a higher quantity of opioid medications, with these incentives linked to the total number of prescriptions filled each day, regardless of their medical justification. The authors argue that pharmacies prioritized their economic gains over their ethical and legal obligations to dispense opioids exclusively for legitimate medical purposes.

Practical Tips

• Engage in open communication with your pharmacist when you pick up prescriptions, asking questions about the medication's purpose, proper usage, and potential interactions with other drugs you're taking. This proactive approach ensures you're using painkillers responsibly and are aware of their effects. You could, for example, ask your pharmacist to explain the best way to taper off a medication to avoid withdrawal symptoms.
• Practice critical thinking by questioning the status quo in everyday situations. If you see long lines at a service provider during off-peak hours, don't just accept it as normal. Consider why this might be happening and what it could indicate about the business or its customers. This habit of questioning can improve your problem-solving skills and help you identify inefficiencies or issues in various settings.
• Develop a habit of regularly reviewing the latest research on pain management and opioid alternatives. Use free online resources such as PubMed or Google Scholar to stay informed about new findings, which can empower you to make evidence-based decisions about your health care and discuss these options with your healthcare provider.

The industry's aggressive marketing tactics, political lobbying, and influence, along with its role in intensifying opioid dependency

The work concludes by reexamining a number of key themes that have been explored throughout its entirety. Higham and Horwitz depict the pharmaceutical industry as prioritizing their financial gain over the well-being of the public, often employing deceptive tactics to do so, even though they are legally required to handle opioid distribution with care.

Companies like Purdue Pharma and Mallinckrodt utilized deceptive marketing tactics to substantially boost the number of prescriptions for opioids aimed at treating persistent pain.

The book highlights how two leading pharmaceutical companies, Purdue Pharma and Mallinckrodt, utilized compelling promotional tactics to assure doctors and patients that the danger of becoming addicted to opioids during prolonged pain treatment was minimal, a claim that was at odds with a century of scientific research and understanding.

They worked alongside pain treatment supporters and paid doctors to spread the misleading idea that the likelihood of becoming addicted to opioids was not as high as it actually was.

Higham and Horwitz describe how companies like Purdue, facing hesitation from physicians to prescribe strong opioid painkillers, set up organizations that purported to represent individuals suffering from persistent pain, but in reality, these groups were often funded and directed by the drug industry's own agents. They also paid physicians, especially those connected with prestigious universities or scientific organizations, to travel across the country and promote the broader application of opioids for the treatment of persistent pain during numerous healthcare workshops and educational events. Numerous physicians inaccurately asserted that the dangers of opioid dependency were exaggerated and often referenced an erroneous report from many years ago, which falsely claimed the likelihood of becoming addicted to opioids was less than one percent among patients treated for chronic pain.

These marketing efforts proved incredibly successful. Higham and Horwitz document the widespread shift in prescribing habits among doctors throughout the 1990s and into the early 2000s, a time when drug manufacturers reaped enormous financial gains.

Context

• The claim that opioids have a low risk of addiction was based on misinterpretations or selective use of data, including a widely cited but flawed letter published in the New England Journal of Medicine in 1980, which was not a comprehensive study.
• The existence of such organizations can erode public trust in legitimate patient advocacy groups. When these groups are exposed as industry-funded, it can lead to skepticism about the motives of all advocacy organizations, even those that are genuinely independent.
• When physicians receive payments or other incentives from drug companies, it can create a conflict of interest, potentially influencing their medical judgment and recommendations to patients.
• The healthcare system's practices, including insurance reimbursements and incentives for prescribing medications, often favored the use of pharmaceuticals, contributing to increased sales and profits for drug manufacturers.

Other Perspectives

• The physicians who referenced the report may not have critically evaluated its findings or sought out additional research before disseminating the information, leading to a biased presentation of the risks.
• Doctors are trained professionals who make decisions based on a variety of factors, including but not limited to pharmaceutical marketing, such as clinical evidence, patient needs, and evolving medical practices.

They utilized marketing tactics that downplayed the likelihood of dependency, misleading medical experts and the public at large.

The marketing initiatives, however, ignored the well-established consensus in the medical community about the significant addiction potential and the possibility of deadly outcomes linked to opioid consumption. The authors note that historically, doctors in the United States have exercised restraint when prescribing opioids, typically reserving such drugs for managing acute pain after surgery or for patients suffering from cancer. Higham and Horwitz contend that the public health crisis was fueled by the forceful marketing strategies of drug companies, in conjunction with the DEA's sanctioning of increased production quotas, actions that expanded access to potent painkillers without adequate oversight or investigation into obvious instances of illicit distribution.

Other Perspectives

• Some companies may have engaged in responsible marketing practices, and it would be inaccurate to generalize the behavior of a few to the entire industry.
• The effectiveness of marketing tactics is influenced by the broader context in which they are received, including prevailing cultural attitudes towards pain management and medication use.
• The interpretation of the medical community's consensus could have evolved over time, with some periods where the understanding of addiction risks was less clear or was under debate.
• The statement does not account for the individual variability in pain tolerance and the complexity of pain management, which might have led to different prescribing practices that do not fit neatly into the historical generalization presented.
• The DEA's decision to sanction increased production quotas might have been based on data and trends at the time that did not clearly indicate a risk of widespread abuse or dependency.
• Investigations into illicit distribution are complex and resource-intensive, which may have limited the ability of agencies to pursue every potential case.

The industry participated in political lobbying and wielded its influence to protect its economic interests, even while the severity of the opioid epidemic increased.

The book details how the pharmaceutical industry persistently markets its products, despite accumulating evidence of their detrimental impacts. They dedicated significant resources to protect their economic stakes at a time when the detrimental effects of the opioid epidemic were becoming more apparent across the country. The book describes the collective strategies employed by the group, which included enlisting numerous lobbyists and attorneys, cultivating ties with staff at the Justice Department, and leveraging the interchange between public service roles and private sector jobs, which collectively undermined the Drug Enforcement Administration's oversight of opioid medication distribution.

The Healthcare Distribution Alliance formulated a strategy that included crafting particular questions for Congress to direct at Rannazzisi, aiming to undermine the regulatory actions of the DEA.

Higham and Horwitz detail how the prominent Healthcare Distribution Alliance formulated a plan in response to the heightened scrutiny from the Drug Enforcement Administration. The Alliance, bolstered by monetary support from leading firms including McKesson, Cardinal, and AmerisourceBergen, employed skilled lobbyists familiar with the complexities of Washington's political landscape, among them former congressional staff and experts from the National Association of Chain Drugstores. The authors emphasize the considerable sway that these lobbyists held in formulating legislation that benefited the sector, such as the establishment of the Marino-Blackburn bill, and in influencing the viewpoints of Congress members. The Alliance hired APCO Worldwide, a public relations firm, to craft the narrative of the industry, focusing on redirecting responsibility for the opioid crisis away from their sector and challenging the attempts by the DEA to regulate it. The book describes how the Alliance devised specific questions for allied lawmakers to ask Rannazzisi and his DEA associates during hearings, aiming to undermine the agency's credibility and obstruct its investigative work.

Higham and Horwitz argue that The Alliance's strategies were highly effective, culminating in the passage of a law in 2016, referred to as the Marino-Blackburn bill, which greatly reduced the Drug Enforcement Administration's power to stop companies from flooding communities with opioids, contrary to their obligations under narcotics regulations.

Context

• These firms are hired to manage the public image of organizations. They craft narratives and strategies to influence public perception and media coverage, often during times of crisis or scrutiny.
• The financial backing from these firms allows the Alliance to exert significant influence over legislative processes, potentially affecting laws and regulations related to drug distribution and control.
• These individuals typically have insider knowledge of legislative procedures and personal relationships with current lawmakers, which can be leveraged to gain access and influence decision-making.
• The HDA is a trade association representing primary pharmaceutical distributors. It plays a crucial role in the supply chain, ensuring that medications are delivered from manufacturers to pharmacies and healthcare providers.
• APCO Worldwide would employ strategic communication techniques such as message framing, media training for industry spokespeople, and targeted outreach to key stakeholders to ensure the industry's perspective was prominently represented in public discourse.
• Joseph Rannazzisi was a former high-ranking official at the DEA who led efforts to regulate and control the distribution of opioids. His work focused on holding pharmaceutical companies accountable for their role in the opioid crisis.
• The Marino-Blackburn bill, officially known as the Ensuring Patient Access and Effective Drug Enforcement Act, was introduced by Representatives Tom Marino and Marsha Blackburn. It aimed to alter the way the DEA could enforce regulations on pharmaceutical companies, particularly concerning the distribution of opioids.
• The bill passed with little opposition in Congress and was signed into law by President Obama, highlighting the influence of pharmaceutical lobbying in shaping drug policy.

The industry channeled substantial financial contributions into the accounts of legislators sympathetic to their cause, thus ensuring support for laws that would lessen oversight over opioid medications.

The writers highlight the industry's primary strategy, which consists of influencing Congress through campaign contributions to secure backing from cooperative lawmakers. They note that the practice of exerting political sway is firmly established within the mechanisms of the nation's capital. Pharmaceutical firms and the HDA, their trade group, funneled significant funds into the political war chests of lawmakers who backed legislation beneficial to their industry, while opposing the efforts of the Drug Enforcement Administration to regulate the sector. Higham and Horwitz emphasize the influence of political power in the U.S. House, noting that the frequency of elections every two years necessitates that legislators spend a significant amount of their time on fundraising for their campaigns.

The book outlines the events of the four years leading up to the enactment of the legislation, a period throughout which Tom Marino and Marsha Blackburn, the main advocates, were given nearly $250,000 in donations from the drug industry.

Other Perspectives

• The focus on financial contributions may overshadow other legitimate forms of engagement and dialogue between the industry and policymakers, such as providing expert testimony, participating in public forums, and contributing to policy research.
• Campaign contributions are subject to federal limits and disclosure requirements, which provide a level of transparency and oversight in the political financing process.
• Some legislators receive contributions from a wide range of sources, including opposing interests, and still make independent decisions based on the merits of the legislation.
• It could be argued that the industry's resistance is not against regulation per se, but against what they perceive as unnecessary or overly burdensome regulations that could stifle innovation and development of new pain management therapies.
• The focus on the influence of political power in the U.S. House may overshadow the role of other branches of government, such as the Senate or the judiciary, which also play critical roles in shaping and interpreting laws.
• Public financing of campaigns in some states and jurisdictions allows legislators to spend less time fundraising.
• The donations over four years could be interpreted as support for the legislators' broader policy agendas rather than a quid pro quo for specific legislation.

The opioid crisis has wrought havoc on human lives as a consequence of the actions taken by the pharmaceutical sector.

The final section of "American Cartel" reflects on the widespread consequences originating from the opioid epidemic, highlighting the significant effects on human life caused by the pharmaceutical sector's conduct. The narrative broadens to include the impact on individuals, the wider social structure, and the collective health consequences stemming from the crisis.

The surge in the number of opioid prescriptions dispensed has contributed to a widespread national emergency, resulting in the loss of many lives across various American neighborhoods.

Higham and Horwitz argue that the pharmaceutical industry's aggressive marketing strategies, coupled with the Drug Enforcement Administration's willingness to increase production quotas, contributed to the proliferation of opioid prescriptions, purportedly due to a rise in clinical necessity. The authors detail the manner in which these corporations inundated American neighborhoods with potent and hazardous opioids, igniting an ongoing epidemic of dependency and fatalities. The writers emphasize that the crisis has resulted in a death toll exceeding half a million American lives, a figure that surpasses U.S. military fatalities from World War II. In 2020, there was a substantial increase in deaths caused by drug overdoses, resulting in 93,000 lives lost. The main substance responsible is fentanyl.

The authors weave together various narratives in their book to illustrate the devastating effects of the crisis on people, featuring Jim Geldhof's experience during a local event in a town within the state of Ohio, where photographs of the departed were displayed while their loved ones mourned, alongside the obstacles encountered by funeral director Rich Bishoff as he endeavored to offer comfort to mourning families in Charleston who found it difficult to afford dignified funerals for their loved ones.

Practical Tips

• You can evaluate your own prescription medications by researching their history and regulatory changes. Look up when the medication was approved, any increases in production quotas, and marketing campaigns associated with it. This will give you a clearer picture of how external factors may have influenced your prescription.
• Implement a personal safety plan that includes regular health check-ups and emergency preparedness. Keep a checklist of health measures to take during a crisis, such as vaccinations and hygiene practices, and maintain an emergency kit with essentials. This proactive approach ensures you and your loved ones are better prepared for any future crises.
• Educate yourself on the signs of overdose and life-saving interventions like naloxone administration by taking a free online course. Understanding the symptoms of a drug overdose and knowing how to administer naloxone, an opioid antagonist that can reverse the effects of an overdose, can prepare you to save lives in an emergency. Look for courses offered by health organizations or local community groups that provide certification upon completion.
• Start a journal to document and reflect on the stories of people in your community who have faced crises. This practice will help you recognize patterns and the impact of crises on a personal level. You might attend community meetings or talk to local business owners and write about the struggles they share, which can be a powerful way to connect with the broader narrative of a crisis.

The disaster severely strained the fabric of community and family ties, pushing the limits of social support systems, law enforcement bodies, and healthcare services to their breaking point.

The authors conclude their book by highlighting the extensive repercussions stemming from the opioid abuse epidemic. The book describes the overwhelming surge of painkillers that has flooded various communities, exerting immense strain on those in law enforcement, the medical field, and public service entities. Higham and Horwitz document the difficulties encountered by law enforcement and emergency responders dealing with a rise in lethal incidents associated with substance abuse, and they also highlight the persistent problem of people relapsing into drug dependency after their initial recovery, which puts additional pressure on treatment facilities and penal establishments.

The authors argue that the social turmoil intensified due to the collapse of industries like coal mining and manufacturing, especially in regions such as Appalachia, where the lack of economic opportunities and continuous unemployment created conditions conducive to a significant rise in dependence on opioids and a widespread feeling of despair. The authors point out that the crisis significantly strained foster care networks, with numerous parents having to give up their children, and a number of infants being born already dependent on opioids, requiring costly medical care.

Practical Tips

• You can strengthen your community ties by initiating a neighborhood skill-share program. Start by creating a simple online board or physical bulletin board in a common area where neighbors can post skills they're willing to teach and skills they want to learn. This could range from gardening tips to basic home repairs, fostering a sense of interdependence and support.
• Educate yourself on the signs of opioid abuse to better recognize and support individuals who may be struggling. By learning the physical and behavioral indicators of opioid misuse, such as changes in mood, sleep patterns, or social withdrawal, you can be more vigilant in your personal and professional circles. If you notice someone exhibiting these signs, you can reach out with empathy and provide information on local support resources.
• Volunteer for a local helpline and provide support for those struggling with substance abuse. By undergoing the necessary training to offer emotional support and guidance over the phone, you can help individuals in crisis and possibly prevent emergency situations from escalating.
• Create a safe space for open dialogue about addiction in your social circles to reduce stigma. Start a book club or discussion group focused on understanding addiction, where members can share experiences and insights without judgment. This could be as simple as inviting friends over for coffee once a month to talk about related topics, fostering a supportive community that can indirectly aid prevention and recovery.
• Engage in conversations with family members or neighbors who experienced the industry collapse firsthand to collect oral histories. This personal approach to understanding the social impact of economic change can be as simple as recording a conversation on your phone. You might discover stories of resilience and adaptation that aren't captured in public discourse, such as how a family member transitioned from a job in manufacturing to a completely different career.
• You can volunteer with local organizations to support economic development and job training in struggling regions. By doing so, you'll be directly contributing to creating opportunities that can alleviate some of the despair linked to unemployment. For example, join a group that teaches coding or other in-demand skills to unemployed individuals, helping them to become more marketable in the job market.
• You can support foster care networks by becoming a certified respite care provider to offer temporary relief for foster parents. Respite care is a service that allows foster parents to take a break, helping to prevent burnout and the potential of them giving up on foster children. To become a respite care provider, you typically need to undergo a background check, complete training, and meet state-specific requirements. This role doesn't require you to commit to full-time fostering but provides invaluable support to the network.
• You can support local organizations that provide assistance to families affected by opioid dependency by donating or volunteering. By contributing to these organizations, you help ensure that infants born dependent on opioids receive the care they need without overburdening the medical system. For example, look for local charities that offer support services or recovery programs for mothers and their children, and contribute either financially or by offering your time to assist with their operations.